U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07115446) titled 'Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer' on Aug. 04.
Brief Summary: HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. HRS-5041 is a Proteolysis Targeting Chimeras (PROTAC) targeting androgen receptors.
This is a phase Ib, open-label, multi-center study to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-20093 combination with HRS-5041 in patients with advanced prostate cancer.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Prostate Cancer
Interven...